Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Settles HPV Suit With Digene

NEW YORK, Jan. 13 (GenomeWeb News) - Third Wave has settled a patent-infringement suit it filed against Digene last fall related to Third Wave's human papillomavirus products, Digene said today.

 

The agreement was made "amicably" and "without the grant of any license or freedom-to-operate under the patents-in-suit and without any effect on the patents-in-suit," Digene said in a statement.

 

The companies have also agreed not to sue each other over HPV patents for one year. The firms stressed that the settlement does not include any license or payment by either company.

As GenomeWeb News reported in October, Third Wave sued Digene in hopes of obtaining a court ruling supporting its right to sell its HPV diagnostics.

"Third Wave wants to clear any remaining ambiguities about the company's freedom to operate in valuable markets like those for ... HPV," John Puisis, former president and CEO of Third Wave, said in a statement at the time. "The value of the Invader chemistry and our pipeline is substantial and we see these actions as a logical progression to protect and expand our market presence."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.